Automated seizure detection for home seizure monitoring with epilog sensors

Ended Cooperative Agreement Awarded Last action

Award ID
U44NS121562
Recipient
Awarding agency
Obligated
$10,944,617

Award facts

Completion date
Originally
Funding
  • $9,944,764.00 Federal
  • $999,853.00 Non-federal
Place of performance
Salt Lake City, UT 84111, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Aura is a digital health platform that uses epilog™, a miniature, wireless, wearable EEG sensor worn on the scalp below hairline that can record clinical and subclinical seizures. After an initial diagnosis of epilepsy, an epileptologist will use known information about patients' seizures to guide the best scalp location to place the epilog EEG sensor (a). EEG data is continuously transferred (b) to the aura APP on a person's smartphone (c) using secure bluetoothtm where IT communicates over wifi (d) to the aura cloud platform (e). Epilog EEG is analyzed for seizures and a daily digital seizure diary is shared with epileptologists (f) and pushed back to the aura APP (g). Epilog is recharged daily, and reusable for a year. Epilog is designed to be discreet, allowing for continuous use in all facets of daily life. Data are a 10 s snippet of the beginning of a focal seizure with motor impairment and intact awareness (ilae 1A1) recorded from epitel's single-channel epilog sensor placed on the left forehead. The patient was admitted for video-EEG monitoring as standard-of-care. This seizure was verified independently by three epileptologists. In phase i, automated, machine learning-based seizure detection algorithms will be designed to first work in the aura cloud to detect seizures in epilog EEG, including seizures a person may not consciously know they are having (>50% of all seizures), such as while sleeping. Aura will run these algorithms developed exclusively for epilog's single-channel of EEG to provide a daily digital seizure diary. In phase II, the aura system will enter clinical validation trials for FDA clearance as an EEG-based automated home seizure detection and alerting system. Early in phase II aura will be commercialized as a medical device-enabled-service business model. Out-of-pocket costs for a person living with epilepsy is an average of $380/year. Armed with long-term, reproducible EEG, epileptologists will now have a more precise, quantitative record of seizure counts, enabling them to adapt patient treatment more rapidly and successfully to improve quality of life. Aura will give people living with epilepsy their lives back. Aura provides certainty where you are and when you need IT. Throughout phase II, physiological, psychological, behavioral, and environmental factors will be combined in the aura APP to collect 27,000 days of multi-modal data from 300 patients to create an unprecedented dataset of features known to precipitate seizures. These data will be used in phase III to create a robust, wearable seizure forecasting system using artificial intelligence that combines multi-modal seizure precipitating factors, creating an hourly seizure probability. Aura will profoundly disrupt how epilepsy is managed and improve the quality of life of people living with epilepsy.

Transactions

Action Federal Non-federal Date
Amendment $1,294,567 $0
Amendment $1,298,163 $0
Amendment $1,683,078 $0
Amendment $1,683,078 $0
Amendment $993,086 $0
Amendment $993,086 $0
Amendment $999,853 $0
Original award $999,853 $999,853

Quick answers

Who received award U44NS121562?

U44NS121562 was awarded to Epitel, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on May 15, 2021.

How much is award U44NS121562 worth?

$10,944,617 has been obligated on U44NS121562: $9,944,764 in federal funding and $999,853 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login